Body mass index and the efficacy of acid-mediating agents for GERD

Digestive Diseases and Sciences

Volumn 53, Issue 9, 2008, Pages 2313-2317

  Jacobson, Brian C ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acid mediating agents; Gastroesophageal reflux disease; Obesity; Proton pump inhibitor

Indexed keywords

CIMETIDINE; CYTOCHROME P450; CYTOCHROME P450 3A; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; OROSOMUCOID; PANTOPRAZOLE; PLACEBO; PROPRANOLOL; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

AREA UNDER THE CURVE; BODY MASS; CLINICAL FEATURE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; GASTROESOPHAGEAL REFLUX; HUMAN; MORBIDITY; OBESITY; PRIORITY JOURNAL; REVIEW;

ANTACIDS; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 50249095624     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0414-8     Document Type: Review

References (33)

1. RA Blouin GW Warren 1999 Pharmacokinetic considerations in obesity J Pharm Sci 88 1 7 10.1021/js980173a
2. G Cheymol 2000 Effects of obesity on pharmacokinetics: implications for drug therapy Clin Pharmacokinet 39 215 231 10.2165/00003088-200039030-00004
3. 85Kr J Appl Physiol 23 621 632
4. N Barak ED Ehrenpreis JR Harrison MD Sitrin 2002 Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations Obes Rev. 3 9 15 10.1046/j.1467-789X.2002.00049.x
5. IH Benedeck A Blouin PJ McNamara 1984 Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects Br J Clin Pharmacol 18 941 946
6. T Andersson 1996 Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole, and pantoprazole Clin Pharmacokinet 31 9 28
7. Feldman M, Burton ME (1990) Histamine2-receptor antagonists. N Engl J Med 323:1672-1680
8. A Somogyi R Gugler 1983 Clinical pharmacokinetics of cimetidine Clin Pharmacokinet 8 463 495
9. KEL McColl P Kennerley 2002 Proton pump inhibitors-differences emerge in hepatic metabolism Dig Liver Dis. 34 461 467 10.1016/S1590-8658(02)80102-5
10. J Horn 2006 Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton-pump inhibitors- focus on pKa and metabolism Aliment Pharmacol Ther Symp Ser 2 340 350 10.1111/j.1746-6342.2006. 00065.x
11. Hoogerwerf WA, Pasricha PJ (2006) Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease. In: Goodman and Gillman's pharmacology, 11th edn. McGraw-Hill, New York
12. AJ Sanyal 2002 AGA technical review on nonalcoholic fatty liver disease Gastroenterology 123 1705 1725 10.1053/gast.2002.36572
13. D Kolwankar R Vuppalanchi B Ethell DR Jones SA Wrighton SD Hall 2007 Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity Clin Gastroenterol Hepatol. 5 388 393 10.1016/j.cgh.2006.12.021
14. RL Davis RW Quenzer HP Bozigian CW Warner 1990 Pharmacokinetics of ranitidine in morbidly obese women Drug Intell Clin Pharm 24 1040 1043
15. DR Abernethy DJ Greenblatt R Matlis R Gugler 1984 Cimetidine disposition in obesity Am J Gastroenterol 79 91 94
16. NI McDougall BT Johnston JS Collins RJ McFarland AH Love 1998 Three- to 4.5-year prospective study of prognostic indicators in gastroesophageal reflux disease Scand J Gastroenterol 33 1016 1022 10.1080/003655298750026688
17. NJ Talley D Armstrong O Junghard I Wiklund 2006 Predictors of treatment response in patients with non-erosive reflux disease Aliment Pharmacol Ther 24 371 376 10.1111/j.1365-2036.2006.02983.x
18. BC Jacobson SC Somers CF Fuchs CP Kelly CA Camargo Jr 2006 Body-mass index and symptoms of gastroesophageal reflux in women N Engl J Med 354 2340 2348 10.1056/NEJMoa054391
19. H Hampel N Abraham H El-Serag 2005 Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications Ann Intern Med 143 199 211
20. Jacobson BC, Delemos B, Sun Y et al (2007) Treatment outcomes with rabeprazole (RAB) 20 mg vs. placebo (PBO) in overweight/obese patients with nonerosive reflux disease (NERD): analysis of 2 US multicenter trials. Gastroenterology 132(suppl 2):A-493 (Abstract)
21. PJ Kahrilas P Miner J Johanson L Mao L Jokubaitis S Sloan 2005 Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease Dig Dis Sci 50 2009 2018 10.1007/s10620-005-3000-3
22. DJ Hetzel J Dent WD Reed FM Narielvala M Mackinnon JH Mc Carthy 1988 Healing and relapse of severe peptic esophagitis after treatment with omeprazole Gastroenterology 95 903 912
23. Jacobson BC, DeLemos B, Sun Y et al (2007) PPI Efficacy in overweight/obese patients with erosive GERD: rabeprazole (RAB) 20 mg vs. omeprazole (OME) 20 mg. Am J Gastroenterol 102:S150 (Abstract 89)
24. F Pace V Annese A Prada A Zambelli S Casalini P Nardini 2005 Italian Rabeprazole Study Group: rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. a randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole Dig Liver Dis 37 741 750 10.1016/j.dld.2005.04.026
25. Sharma P, Vakil N, Monyak JT et al (2007) Effect of obesity on symptom resolution in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 102:S139-S140 (Abstract 61)
26. Vakil N, Sharma P, Monyak JT et al (2007) Is obesity the cause of reduced healing rates in advanced grades of erosive esophagitis (EE)? Am J Gastroenterol 102:S445 (Abstract 889)
27. WH Wang JQ Huang GF Zheng WM Wong SK Lam J Karlberg 2005 Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain? a meta-analysis Arch Intern Med 165 1222 1228 10.1001/archinte.165.11.1222
28. ME Numans J Lau NJ de Wit PA Boris 2004 Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Ann Intern Med 140 518 527
29. LJ Wilson W Ma BI Hirschowitz 1999 Association of obesity with hiatal hernia and esophagitis Am J Gastroenterol 94 2840 2844 10.1111/j.1572-0241.1999. 01426.x
30. JE Pandolfino HB El-Serag Q Zhang N Shah SK Ghosh PJ Kahrilas 2006 Obesity: a challenge to esophagogastric junction integrity Gastroenterology 130 639 649 10.1053/j.gastro.2005.12.016
31. JC Wu LM Mui CM Cheung Y Chan JJ Sung 2007 Obesity is associated with transient lower esophageal sphincter relaxation Gastroenterology 132 883 889 10.1053/j.gastro.2006.12.032
32. HI Pirttiaho PI Salmela EA Sotaniemi RO Pelkonen U Pitkänen PV Luoma 1984 Drug metabolism in diabetic subjects with fatty livers Br J Clin Pharmacol 18 895 899
33. I Leclercq Y Horsmans JP Desager N Delzenne AP Geubel 1998 Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation J Hepatol 28 410 416 10.1016/S0168-8278(98)80314-0